

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/672,280
				Filing Date	September 26, 2003
				First Named Inventor	Lazar et al.
				Art Unit	1644 / Conf No. 8317
				Examiner Name	DAHLE, Chun Wu
				Attorney Docket Number	067461-5121-US
Sheet	1		3		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-2003/0073164 A1	4-17-2003	Simmons et al.	
	A2	US-2007/0148164	06-2007	Farrington et al.	
	A3	US-5,530,101	06-1996	Queen et al.	
	A4	US-6,992,234 B2	01-31-2006	Roopenian	
	A5	US-6,284,536 B1	09-04-2001	Morrison et al.	
	A6	US-2007/0238665	10-2007	Lazar et al.	
	A7	US-2007/0224192	09-2007	Lazar et al.	
	A8	US-2008/0206867	08-2008	Desjarlais et al.	
	A9	US-2004/0093621	05-2004	Shitara et al.	
	A10	US-2004/0132101	7-2004	Lazar et al.	
	A11	US-2008/0071063	03-2008	Allan et al.	
	A12	US-2007/0087005	04-2007	Lazar et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	B1	WO99/54484A1	10-28-1999	The Regents of the University of California		
	B2	WO02/066514 A	08-29-2002	Merck		
	B3	WO02/079732 A2	10-10-2002	Lexigen Pharm Corp.		
	B4	WO04/063963 A	07-29-04	Xencor, Inc.		
	B5	WO04/099249 A	11-18-2004	Xencor, Inc.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified)		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/672,280
		Filing Date	September 26, 2003
		First Named Inventor	Lazar et al.
		Art Unit	1644 / Conf No. 8317
		Examiner Name	DAHLE, Chun Wu
		Attorney Docket Number	067461-5121-US
Sheet	2	3	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C1	BASTIDA-CORCUERA, et al., "Differential complement activation by bovine IgG2 allotypes" <i>Veterinary Immunology and Immunopathology</i> , 1999, Vol. 61 No. 2, 115-123	
	C2	BURTON, ET AL. "Immunoglobulin G: Functional sites", <i>Molecular Immunology</i> , vol. 22, no. 3, (March 1985)	
	C3	CHAN, et al. "Variable Region Domain Exchange in Human IgGs promotes antibody complex formation with accompanying structural changes and altered effector functions" <i>Molecular Immunology</i> 2004, 21:527-538	
	C4	CHIRINO, A.J. et al. "Minimizing the immunogenicity of protein therapeutics", <i>Drug Discovery Today</i> , 2004, Vol. 9, no. 2, pps. 82-90	
	C5	COLE, M.S., et al., "HUM291, a Humanized Anti-CD3 Antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro", <i>Transplantation</i> , Vol. 68, no. 4, pp. 563-571 (1999)	
	C6	DAHIYAT, B. I. et al. "Protein Design Automation", <i>Protein Science</i> , 1996, vol. 5, no. 5, ps. 895-903	
	C7	DALL'ACQUA, W. et al. "Modulation of the Effector Functions of a Human IgG1 through Engineering of Its Hinge Region", 2006, <i>J. Immunology</i> , 177:1129-1138.	
	C8	KABAT et al., NIH Pub. No. 91-3242, p. 679-687 (1991)	
	C9	KATO, K. et al., "Analysis of IgG-FcγR interactions in solution: Mapping of the FcγR binding site and evidence for a conformational change occurring in the Fc region", <i>Immunology Letters</i> , Vol. 73, no. 2-3 (2000)	
	C10	Lazar, et al. "Engineered antibody Fc variants with enhanced effector function" <i>PNAS</i> , 2006, 4005-4010	
	C11	MORRISON, et al. "Variable Region Domain Exchange Influences the Functional Properties of IgG" <i>The Journal of Immunology</i> 1998, 160:2802-2808	
	C12	NATSUME, A. et al. "Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities", 2008, <i>Cancer Research</i> , 68(10) pp. 3863-3871.	
	C13	PENDLEY C. et al., "Immunogenicity of therapeutic monoclonal antibodies", <i>Current Opinion in Molecular Therapeutics</i> , 2003, vol. 5, no. 2, pps. 172-179	
	C14	SHITARA ET AL. "A new vector for the high level expression of chimeric antibodies in myeloma cells" <i>J. of Immunological Methods</i> , 1994, 167: 271-278	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified)				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/672,280
				Filing Date	September 26, 2003
				First Named Inventor	Lazar et al.
				Art Unit	1644 / Conf No. 8317
				Examiner Name	DAHLE, Chun Wu
Sheet	3		3	Attorney Docket Number	067461-5121-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C15	TAMM, A. et al., "IgG Binding Sites on Human Fcγ Receptors" 1997, <i>International Reviews of Immunology</i> , 16:1,57-85	
	C16	VALERIUS, T. et al., "FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy" <i>Blood</i> , 1997, 90:4485-4492	
	C17	VITETTA, E., et al., "Considering Therapeutic Antibodies", <i>Science</i> , 2006, Vol. 313, pp. 308-309	
	C18	WHO Review of the notation for the allotypic and related markers of human immunoglobulins. <i>J Immunogen</i> 1976, 3:357-362;	
	C19	WHO Review of the notation for the allotypic and related markers of human immunoglobulins. 1976, <i>Eur. J. Immunol.</i> 6, 599-607;	
	C20	WOOF, J.M. et al. "Localisation of the Monocyte-Binding Region on Human Immunoglobulin G" <i>Molecular Immunology</i> , 1986, Vol. 23, No. 3, pp. 319-330	

DB2/21715802.1

Examiner Signature	/Chun Dahle/ (05/24/2010)	Date Considered	
--------------------	---------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2